Blog | Veristat Insightful Perspectives

Summary of Key Considerations Outlined in the Third Edition of the EMA Guidance

The European Medicines Agency (EMA) has now published its third version of the Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic.  This guidance addresses the need for sponsors to change the execution of clinical trials during the global COVID-19 pandemic response. 

An Interview with Dunya Botetzayas, RN, Senior Director of Clinical Monitoring at Veristat

Site Selection to Protocol Development: An Approach to the Feasibility Process

How does the site feasibility study process work at Veristat? 

Our process starts from the RFP stage. We usually send a feasibility questionnaire to the site prior to the study award, to get an in-depth assessment of feasibility at the RFP stage.